What is the new agreement between Echo IQ (ASX: EIQ) and the Mayo Clinic?

Echo IQ has expanded its existing partnership with the Mayo Clinic to transform the prestigious US medical group into a primary reseller and distributor of its EchoSolv HF technology. The revised framework includes improved commercial terms and an automatic renewal clause that extends the potential partnership to six years.

How does this news affect the investment thesis for Echo IQ (ASX:EIQ)?

This agreement shifts Echo IQ from a development-focused med-tech firm toward a commercially ready entity with a high-tier distribution partner. By securing a six-year potential term and access to Mayo's network of over 80 partner hospitals, the company has established a scalable pathway for US revenue generation.

What is EchoSolv HF and why is it commercially significant?

EchoSolv HF is an AI-driven clinical decision support solution designed to identify patients suffering from heart failure. It addresses a massive diagnostic gap in the US, where approximately 50% of heart failure cases are currently inaccurately diagnosed.

What were the results of the Echo IQ (ASX:EIQ) validation study?

In a clinical validation study conducted through the Mayo Clinic Platform, EchoSolv HF demonstrated a sensitivity of 99.5% and a specificity of 91.1%. These metrics indicate the AI is highly effective at both identifying true positive cases of heart failure and correctly ruling out patients without the condition.

Has Echo IQ (ASX: EIQ) received FDA clearance for EchoSolv HF?

No, EchoSolv HF is not yet cleared by the US Food and Drug Administration (FDA), though the company has lodged its 510(k) premarket notification. The current commercial agreement with the Mayo Clinic is structured to commence full deployment specifically following the receipt of this regulatory clearance.

How will the Mayo Clinic distribute Echo IQ’s technology?

The Mayo Clinic will deploy EchoSolv HF through its "Solutions Studio Program," part of the broader Mayo Clinic Platform. This enables distribution not only within Mayo’s own hospitals and health system network but also to more than 80 external partner hospitals.

What are the key bull and bear points for Echo IQ (ASX: EIQ) after this news?

The bull case focuses on the "Mayo Clinic seal of approval" and the high sensitivity/specificity results which suggest a superior product. The bear case remains centered on regulatory risk; if the FDA delays or denies the 510(k) clearance, the commercial agreement cannot be fully realised.

What is the market opportunity for heart failure diagnostics in the US?

The US market represents a substantial burden on the healthcare system, with 6.7 million current cases and upwards of 16 million echocardiograms performed annually. Echo IQ estimates that 2 million patients remain undiagnosed, representing a significant untapped market for AI diagnostic tools.

Health

Image for illustrative purposes only. Not a real photo.

Echo IQ expands Mayo Clinic heart AI partnership

Written by Isaac FrancisPublished Mar 24, 2026, 3:14 AMLast Updated Jul 6, 2026, 10:31 AM

Australian medical technology innovator Echo IQ (ASX: EIQ) has strengthened its commercial ties with the Mayo Clinic, announcing an expanded agreement to distribute its AI-driven heart failure solution, EchoSolv HF.

The revised framework positions the Mayo Clinic to act as a primary reseller and distributor of the technology across its extensive healthcare network and through the Mayo Clinic Platform – Solutions Studio Program.

The partnership now includes more favourable commercial terms and an automatic renewal clause that extends the potential collaboration to six years, signalling a robust long-term commitment between the two entities.

The strategic expansion follows a successful validation study where EchoSolv HF demonstrated a remarkable sensitivity of 99.5% and a specificity of 91.1% in identifying heart failure patients.

While the results await final FDA review, the company has already lodged a 510(k) premarket notification.

Once cleared, the distribution through the Mayo Clinic Platform will provide a scalable pathway into over 80 external partner hospitals, addressing a critical gap in US healthcare.

Currently, heart failure affects approximately 6.7 million Americans, yet nearly half of all cases remain inaccurately diagnosed.

Echo IQ aims to unlock a market opportunity while improving outcomes for the one in four Americans expected to develop heart failure in their lifetime.

At the time of reporting, Echo IQ’s share price was $0.72.

Echo IQ expands Mayo Clinic heart AI partnership

Frequently asked questions

Assets related to this article